Sight Sciences Inc Dossier
Qualitative Analysis
Business overview
Sight Sciences, Inc. (NASDAQ: SGHT) is an ophthalmic medical device company focused on developing and commercializing innovative, interventional technologies designed to transform care and improve patients' lives. The company operates through two primary segments: Surgical Glaucoma and Dry Eye. Its Surgical Glaucoma segment features the OMNI Surgical System, an implant-free, minimally invasive glaucoma surgery (MIGS) technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The segment also includes the SION Surgical System, a bladeless, manually operated instrument used in goniotomy procedures. Its Dry Eye segment offers the TearCare System, a 510(k)-cleared localized heat therapy system designed to clear meibomian gland obstructions, addressing the leading cause of evaporative dry eye disease.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the sales and clinic support teams for the TearCare System, with an intense focus on driving utilization and account activation in the First Coast and Novitas regions where Medicare reimbursement is active.
Expected impact: Aims to scale Interventional Dry Eye revenue to $6.0 million - $8.0 million in 2026, up from $1.6 million in 2025.
Developing the underpenetrated standalone pseudophakic MIGS (Micro-Invasive Glaucoma Surgery) segment for the OMNI Surgical System, moving beyond combination cataract procedures.
Expected impact: Drives market share gains and mitigates the impact of Medicare LCD restrictions on combination procedures.
Preparing for the commercial rollout and adoption of the differentiated OMNI Ultra product line.
Expected impact: Provides a highly differentiated technology to interventional glaucoma accounts, though not yet factored into near-term 2026 guidance.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Established jurisdiction-wide local Medicare fee schedules for CPT code 0563T (TearCare), covering 12 states/regions and approximately 8.0 million Medicare lives.
Terms: Effective for dates of service on and after January 1, 2025.
Established jurisdiction-wide local Medicare fee schedules for CPT code 0563T (TearCare), covering Florida, Puerto Rico, and the Virgin Islands (approximately 2.4 million Medicare lives).
Terms: Effective for dates of service on and after January 1, 2025.